Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Immunomedics Expands Partnership With Roche on Lung Cancer Treatments

share with twitter share with LinkedIn share with facebook
07/13/2020 | 05:08pm EDT

By Kimberly Chin

 

Immunomedics Inc. said it has extended its partnership with Roche Holding Ltd. on clinical trials of their combined treatments for patients with metastatic urothelial cancer and metastatic non-small cell lung cancer.

The two companies will look at the efficacy of Immunomedics' Trodelvy treatment in combination with Roche's Tecentriq.

Roche will conduct two open-label, randomized Phase 1b/2 studies that will examine patients who have failed platinum-containing chemotherapy and have begun using Tecentriq and Trodelvy together, as well as patients who use Tecentriq alone. A second study will look at patients who take the combined treatments and docetaxel alone.

Separately, Immunomedics said it will launch a Phase 2 study of Trodelvy for its first patient who has localized triple-negative breast cancer. The treatment will be administered before tumor-removal surgery, the company said. The primary aim of the study will be to show a pathological complete response rate to the treatment, Immunomedics said.

 

Write to Kimberly Chin at kimberly.chin@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
IMMUNOMEDICS, INC. -1.17% 44.045 Delayed Quote.109.88%
ROCHE HOLDING AG -1.22% 320.45 Delayed Quote.3.31%
THE PLATINUM GROUP 0.79% 2.54 End-of-day quote.-37.75%
share with twitter share with LinkedIn share with facebook
Latest news on ROCHE HOLDING AG
08:55aSPARK THERAPEUTICS : Recognized for Fourth-straight Year as One of Philadelphia'..
AQ
08:03aROCHE : Eastern Ontario Regional Laboratory Association (EORLA) and Roche Diagno..
AQ
08/03ROCHE HOLDINGS AG : JP Morgan reaffirms its Buy rating
MD
08/03Rival drugmakers launch joint trial of medicines for COVID-19
RE
08/03ROCHE : Princeton's Prud'homme and Yang partner with Genentech to decode a key p..
AQ
08/03Rozlytrek, Roche's first tumour-agnostic therapy, approved in Europe for peop..
GL
08/02ROCHE : gets European marketing approval for cancer treatment Rozlytrek
RE
07/31GLOBAL MARKETS LIVE: A flurry of earnings reports, day 3
07/31ROCHE : FDA Approves Genentech's Tecentriq plus Cotellic and Zelboraf for People..
AQ
07/31FDA approves Roche's Tecentriq plus Cotellic and Zelboraf for people with adv..
GL
More news
Financials
Sales 2020 61 774 M 67 480 M 67 480 M
Net income 2020 15 311 M 16 725 M 16 725 M
Net cash 2020 3 476 M 3 797 M 3 797 M
P/E ratio 2020 19,2x
Yield 2020 2,89%
Capitalization 277 B 301 B 303 B
EV / Sales 2020 4,43x
EV / Sales 2021 4,16x
Nbr of Employees 97 735
Free-Float 82,8%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 380,68 CHF
Last Close Price 324,40 CHF
Spread / Highest target 28,5%
Spread / Average Target 17,3%
Spread / Lowest Target 0,18%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG3.31%300 745
JOHNSON & JOHNSON1.01%387 947
PFIZER, INC.-2.12%213 028
MERCK & CO., INC.-9.25%208 339
NOVARTIS AG-15.79%185 171
ABBVIE INC.8.36%169 079